Commercial-stage biopharmaceutical company Agios Pharmaceuticals Inc. (AGIO) is on the cusp of a milestone that could redefine its market position. With the U.S. Food and Drug Administration (FDA) setting December 7, 2025, as the Prescription Drug User Fee Act (PDUFA) goal date for PYRUKYND's supplemental New Drug Application (sNDA) in thalassemia, market watchers are bracing for a pivotal decision. The outcome has the potential to reshape Agios's commercial profile and reestablish confidence in a stock that recently touched a 52-week low.
PYRUKYND: The PDUFA Spotlight
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com